How is Sacituzumab Govitecan Hziy Intravenous Route dosed?
The recommended dosage for metastatic triple-negative breast cancer is 875 mg/m^2 administered as an intravenous infusion over 30 minutes every 3 weeks. For metastatic hormone receptor-positive, HER2-negative breast cancer, the recommended dosage is also 875 mg/m^2 administered as an intravenous infusion over 30 minutes every 3 weeks. The dosage is determined by a healthcare professional based on the individual patient's condition and medical history.
What is the dosage form of Sacituzumab Govitecan Hziy Intravenous Route?
This medication is available in the form of a powder for solution.
What medications are contraindication with Sacituzumab Govitecan Hziy Intravenous Route?
It is important to inform your doctor about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions. Your doctor will be able to advise you on any contraindicated medications based on your specific medical history and conditions.
How is Sacituzumab Govitecan Hziy Intravenous Route administered?
This medication is administered through the intravenous route, which means it is given directly into a vein through a needle or catheter. It is typically administered by a healthcare professional in a clinical setting, such as a hospital or medical office.
What are common precautions when taking Sacituzumab Govitecan Hziy Intravenous Route?
Common precautions when taking this medication include regular monitoring of your progress, blood tests to check for potential side effects, administration only by a doctor or under their immediate supervision, and possible dosage adjustments or other precautions if any interactions with other medications occur. Please consult your doctor for specific precautions and instructions regarding your use of this medication.